| chronic pain (diagnosis)
Lyrica vs Belbuca
Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).Deep comparison between: Lyrica vs Belbuca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBelbuca has a higher rate of injection site reactions vs Lyrica based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Belbuca but not Lyrica, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lyrica
Belbuca
At A Glance
Oral
2-3 times daily
alpha2-delta calcium channel ligand
Buccal film
Every 12 hours
Partial opioid agonist
Indications
- Peripheral Nervous System Diseases
- Epilepsy
- Fibromyalgia
- chronic pain (diagnosis)
- chronic pain (diagnosis)
Dosing
Peripheral Nervous System Diseases Begin at 150 mg/day in 3 divided doses; may increase to max 300 mg/day within 1 week; oral.
chronic pain (diagnosis) PHN: begin at 150 mg/day (75 mg BID or 50 mg TID), max up to 600 mg/day. Spinal cord injury neuropathic pain: begin at 150 mg/day (75 mg BID), max 600 mg/day; oral.
Epilepsy Adults: begin at 150 mg/day in 2 or 3 divided doses, max 600 mg/day. Pediatric >=30 kg: begin 2.5 mg/kg/day, max 10 mg/kg/day. Pediatric <30 kg: begin 3.5 mg/kg/day, max 14 mg/kg/day; oral.
Fibromyalgia Begin at 150 mg/day (75 mg BID); may increase to 300 mg/day within 1 week; max 450 mg/day; oral.
chronic pain (diagnosis) 75 mcg buccal film once daily or every 12 hours for opioid-naive patients, titrated in increments of 150 mcg every 12 hours no more frequently than every 4 days to a maximum of 900 mcg every 12 hours; initial dose for opioid-experienced patients: 150 mcg every 12 hours (30-89 mg oral MSE) or 300 mcg every 12 hours (90-160 mg oral MSE).
Contraindications
- Known hypersensitivity to pregabalin or any of its components
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity (e.g., anaphylaxis) to buprenorphine
Adverse Reactions
Most common (>=5%) Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal
Serious Angioedema, hypersensitivity, suicidal behavior and ideation, respiratory depression, peripheral edema, weight gain, tumorigenic potential, ophthalmological effects, creatine kinase elevations, decreased platelet count, PR interval prolongation
Postmarketing Headache, nausea, diarrhea, gynecomastia, breast enlargement, bullous pemphigoid, life-threatening respiratory depression with opioids or CNS depressants
Most common (>=5%) Nausea, constipation, headache, vomiting, fatigue, dizziness, somnolence
Serious Addiction, abuse, and misuse; life-threatening respiratory depression; interactions with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; QTc prolongation; hepatotoxicity; anaphylactic/allergic reactions; seizures
Postmarketing Serotonin syndrome, adrenal insufficiency, anaphylaxis, androgen deficiency, hyperalgesia and allodynia, dental decay (caries, tooth fracture, and tooth loss), hypoglycemia, opioid-induced esophageal dysfunction
Pharmacology
Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues, reducing calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord and exerting antiseizure effects; it is a structural GABA analogue but does not act directly on GABA receptors, sodium channels, or opiate receptors.
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor; it produces analgesia by binding with high affinity to opioid receptors on neurons in the brain and spinal cord and, unlike full opioid agonists, exhibits a dose-ceiling effect on respiratory depression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lyrica
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (9/12)
Belbuca
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lyrica
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Belbuca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lyrica
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Belbuca
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lyrica.
No savings programs available for Belbuca.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LyricaView full Lyrica profile
BelbucaView full Belbuca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.